Clinical Trial Update: First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update indicates that Prestige Biopharma's anti-PAUF monoclonal antibody PBP1510 is entering a first-in-human Phase 1/2a study in pancreatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• PBP1510 (anti-PAUF monoclonal antibody)

Snippet

Sponsor: Prestige Biopharma Limited | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: RECRUITING